








Identification of Human Biomarkers for Cocaine Addiction Diagnosis 














Addiction is a result of long-lasting behavioral changes including tolerance (the need for 
escalating doses to achieve the same effect) and dependence (physical symptoms manifested 
during abstinence). It is estimated that 35.3 million Americans have tried cocaine at least once, 
6.1 million have used in the past year, and 2.4 million have used it in the past month according to 
the National Household Survey on Drug Abuse report in 2006, indicating the need for accurate 
diagnosis of dependence among a large portion of the population. It is important to diagnose 
cocaine use and dependence by finding definitive markers, termed biomarkers, of such a disease 
state. For comparison, blood tests for the presence of cocaine are only effective for the 20 
minutes to several hours that the drug remains in the body. At present diagnosis of cocaine 
dependence requires subjective psychological and physical testing and interviews. The goal is to 
use microarrays to identify a specific set of biomarkers which can reliably determine a diagnosis 
of cocaine addiction. The impact of this research includes development of novel 
pharmacotherapies to prevent addiction and relapse and to improve the quality of life and 
productivity of addicted and recovering individuals and their communities. 
This experiment uses global gene expression analysis to identify changes in the RNA of 
cocaine addicts versus non-addicted individuals. Total RNA is extracted from whole blood 
samples, purified, hemoglobin transcripts are removed, and RNA is quantified with Nanodrop 
spectroscopy. The RNA is the hybridized to oligonucleotide microarrays containing 49,000 
genes. This project will ultimately produce useful data on diagnostic biomarkers of cocaine 
addiction. It can help clinicians to diagnose addicts and to determine what drugs a patient has 
been using long term. The project is a collaboration that will identify correlations between gene 
expression patterns and subject behavior as reported by UTMB Galveston and UTHSC-Houston, 
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thus enabling unambiguous diagnosis of addiction. My role in the project is to obtain high 
quality, ultra pure RNA from whole blood samples, with the goal of discovering biomarkers of 
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Cocaine is a naturally-occurring alkaloid from the leaves of Erythroxyyon coca, a plant 
whose leaves, shown in Figure 1, have been chewed by South Americans for approximately 5000 
years (Feldman et al, 1997). Cocaine was chemically extracted from the leaf in 1859, after which 
it was used in many substances. There are several forms of cocaine, including the raw leaf, a 
crystalline powder, and the free base form, crack cocaine. Purified cocaine is stable as a 
hydrochloride salt that forms a crystalline powder, shown in Figure 2(a), which is usually snorted 
or injected. Pure cocaine is also stable as the free base form (including crack cocaine, shown in 
Figure 2(b)), which can be smoked.  
 
Figure 1: Leaves of Erythroxyyon coca 
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Figure 2. (a) Cocaine powder (b) Crack cocaine  
 
Historically unregulated cocaine-containing formulations included: Coca-Cola, originally 
prepared with a recipe that called for cocaine extract, cocaine toothache drops marketed at very 
young, teething children for cocaine’s anesthetic properties, and Vin Mariani, endorsed by Pope 
Leo XIII, who carried a hip flask of this wine, (Figure 3). After increasing popularity of the use 
of cocaine, its addictive properties were realized. Consequently, in 1914, the Harrison Narcotics 
Tax Act made the sale of cocaine illegal in the United States. However, there are some legal uses 
of cocaine today, such as in topical anesthetics (Aldous et al, 1998). Cocaine, along with 
benzocaine, novacaine, and lidocaine, cause local anesthesia by blocking voltage gated sodium 
channels in the neuron plasma membrane (Ahern et al, 2008). Cocaine acts as a topical 
anesthetic at high doses (4% cream applied locally, Aldous et al 1998), and was traditionally 
used in eye and nasal surgery for this reason.  
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Figure 3: (a) Coca-Cola advertisement, (b) Cocaine toothache drops, (c) Vin Mariani 
endorsement.  
 
Medical and Behavioral Effects 
Cocaine is a psychomotor stimulant, which means with short term use it increases 
alertness as well as motor activity (Feldman et al, 1997). Cocaine also causes local anesthesia 
due to the blockage of sodium channels. With long term use, cocaine induces behavioral changes 
including compulsive, stereotyped motor activity such as head bobbing and tongue movement, 
psychotic behavior similar to schizophrenia, and hallucinations. One common hallucination is of 
insects crawling under the skin; users will scratch and cut themselves to get the “crack bugs” out 
(Cesar). Other long term effects of cocaine include a high risk of cerebro-ventricular accident or 
stroke and convulsions (Koppel et al, 1996).  
Cocaine addiction is a disease characterized by dependence, which, defined for alcohol, 
is diagnosed by the presence of three or more subjective symptoms (DSM-IV). They include: the 
need for more drug for same effect (tolerance), craving or withdrawal syndrome or use of the 
drug to prevent withdrawal symptoms, desire or effort to reduce usage, using more than 
intended, important lifestyle activities reduced by drug use, significant time spent using or 
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recovering from using, and drug use despite physical and/or psychological problems directly 
caused by the drug. These criteria can be broadly applied to all addictive substances.  
Cocaine dependence causes lethargy, depression, and an increased probability of fatal 
overdose (Feldman et al, 1997). Cocaine acts very quickly to achieve a high, and the low 
similarly occurs rapidly. Dysphoria leads to craving for more cocaine soon after use by an addict, 
which in turn leads to multi-dose binges lasting hours. Cocaine is rewarding in the short term 
because it blocks monoamine transporters in brain regions important in reward and 
reinforcement. This blockage prolongs neurotransmitters’ action at their receptors. The primary 
neurotransmitter involved in these brain regions is dopamine. This brain imbalance, in the long 
term, has drastic consequences for the health of the user.  
Eighty-three million dollars was spent on hospitalization of cocaine users in 1995, with 
the most common symptom being chest pain associated with myocardial infarction (Drug Abuse 
Warning Network, 2001). In 2000, approximately 175,000 cocaine-related visits were made to an 
emergency department in the United States (DAWN, 2001). In addition, cocaine dependence can 
be passed on to a fetus in the womb. Each addicted baby born of an addicted mother costs 
medical and social systems $750,000 to $1.5 million (Kalotra, 2002). Obviously, accurate 








Molecular Effects: Gene Transcription and Expression 
How does cocaine cause such diverse clinical aspects, as outlined above? The primary 
neurochemical effect of cocaine dosage is increased synaptic concentrations of the reward 
neurotransmitters dopamine and serotonin, and the stimulatory neurotransmitters norepinephrine 
and epinephrine (Feldman et al, 1997). Cocaine blocks all these monoamine transporters, 
preventing reuptake of neurotransmitters for recycling. The psychomotor effects of cocaine are 
specifically associated with dopamine systems. The dopamine transporter and the structure of 
cocaine and of dopamine are illustrated in Figure 4 to indicate their interaction. Addiction alters 
neuronal transmission and synaptic structure and organization through neurotransmitters, 
sometimes permanently (Figure 5).  
 
 
Figure 4. (a) Dopamine transporter (b) Dopamine molecule (c) Cocaine molecule 
Note the structural similarities of dopamine and cocaine, especially the benzene ring and the 






Figure 5. Organization and regulation of dopamine transporter and receptors 
 
Furthermore, neurotransmitters and neuromodulators activate receptors, which can then 
activate second messengers such as calcium and cAMP (cyclic adenosine 3,5-monophosphate) 
(Dube and Amireault, 2007). Second messengers can affect gene expression by activating 
transcription factors such as CREB (cAMP response element binding protein) to enhance or 
suppress transcription of DNA. In this way, cocaine and other drugs of abuse can alter gene 
expression.  
Cocaine responsive genes have previously been identified in mouse brain studies 
(Freeman et al, 2007). The categories of genes were involved in neurological signaling pathways. 
These genes are transcribed from DNA to messenger RNA transcripts, which in turn are 
translated to proteins with diverse functions which ultimately play a significant role in cellular 
function (Hartwell et al, 2004). The expression of genes is primarily regulated at the point of 
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initiation of transcription. Proteins called transcription factors bind to the DNA for regulation. 
Messenger RNA for proteins is encoded by Class II genes, which contain regulatory regions 
called promoters and enhancers. Promoters are located at the 5’ end (the phosphate end) of the 
gene of interest, whereas enhancers may be located in a number of regions with respect to their 
gene. Regulation of transcription depends on interaction of multiple enhancers with competing 
transcription factors. This integration of signals determines the precise level of transcription of a 
specific gene in a specific cell at a specific time (Hartwell et al, 2004).  
 
Genetic Factors 
 In addition to altering genetic expression, cocaine addiction has a genetically inherited 
component. Genetic factors are estimated to account for 40-60% of addiction risk (Nestler, 
2000). One important goal is identification of human genetic and biological traits that diagnose 
addiction. Quantitative trait locus analysis in animal models can be used to map behaviors to 
specific genes. Some researchers are searching for genes of susceptibility to addiction as well. 
Once discovered, these genes are investigated in animal and other models. Of course, the 
complex trait of addiction involves many genes, each contributing some small effect to what can 









Short-term biomarkers can easily be quantified by urinalysis and other tests. Short-term 
biomarkers of cocaine use, such as the pyrolyzate metheylecgonidine and its metabolite 
ecgonidine have half-lives of 18-21 minutes and 94-127 minutes, respectively (Scheidweiler, 
2003). These molecules (Figure 6) are specifically associated with smoking cocaine only, due to 
the heat-activated conversion of cocaine to methylecgonidine. Methylecgonidine is an in vitro 
muscarinic agonist, which means it stimulates the production of nitric oxide in cardiac tissues, 
causing the smooth muscle of blood vessels to relax, and permitting vasodilation to increase 
blood flow. This biomarker can be found in urine, saliva, and perspiration, but its short life is it 
main disadvantage.  
 
Figure 6. Short-term biomarkers of cocaine smoking (Scheidweiler, 2003) 
 
Cocaine dependence is a complicated condition, and as such, a single biomarker is 
unlikely to serve as a reliable diagnostic indicator. It is important to use RNA to identify 
biomarkers of addiction (a biomarker is any molecule, whether protein, RNA, or other 
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metabolite, that acts as a definitive signal of a particular disease state), because RNA levels are 
indicative of upregulation and downregulation of genetic expression. A specific pattern of 
changes in gene expression may act as a diagnostic biomarker. This experiment aims to discover 
such a pattern using RNA from whole blood samples from cocaine dependent individuals. 
Human erythrocytes lack nuclei, so the vast majority of RNA is from the leukocytes.  
 Animal studies have shown that even after long-term abstinence (30 or 100 days), 
cocaine reinforcement persists due to changes in RNA expression levels (Freeman, 2007). These 
results demonstrate altered gene expression after cocaine administration and abstinence. Changes 
in gene expression persist long after cessation of drug consumption, and may be associated with 
repeated relapses among addicted individuals. Regulation of gene expression, including 
















 This experiment will identify transcriptional changes to diagnose the disease state of 
cocaine addiction. Blood samples were supplied by the University of Texas Medical Branch in 
Galveston and the University of Texas Health Science Center at Houston. Multiple drug use is a 
common problem among cocaine dependent individuals. The 116 patients in the clinical study 
can be categorized by:  
• Cocaine dependence (only) 
• Cocaine dependence with alcohol dependence 
• Cocaine dependence with Cannabis use 
• Cocaine dependence with opiate dependence 
 
RNA Extraction from Whole Blood 
This experiment uses global gene expression analysis to identify changes in RNA levels 
of cocaine addicts versus non-addicted individuals. Total RNA is extracted from whole blood 
samples, purified, hemoglobin transcripts are removed, and RNA is quantified with Nanodrop 
spectroscopy. The goal is to obtain high quality, ultra pure RNA from whole blood samples, to 
identify patterns of gene expression that may be used as biomarkers.  
  Four milliliter blood samples are obtained from patients enrolled in ongoing clinical 
trials. Total RNA is extracted and purified with a PAXgene Blood RNA Kit shown in Figure 7 
(Qiagen, USA) through centrifugation, resuspension, and incubation with proteinase, then DNase 
to remove all  cellular fractions that lack RNA. Nanodrop spectroscopy quantifies the RNA, 
which is critical because 1 µg is required for microarray hybridization. The 260/280 and the 
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260/230 ratios reveal the RNA content of the elution.  
 
Figure 7. PAXgene RNA extraction from blood (Qiagen) 
 
 
Globinclear Transcript Removal 
Approximately 70% of the RNA in human blood is hemoglobin mRNA, which dilutes the 
other transcripts and produces a saturated signal if used for microarray analysis. Thus, after 
ethanol precipitation to concentrate the solution, the globin transcripts were removed using a 
commercially available kit shown in Figure 8 (GLOBINclear kit from Ambion, USA). By 
removing globin transcripts, the signal lost is compensated by the magnitude of signal gained for 
every other transcript. The hemoglobin RNA is biotinylated, and the biotin binds magnetic 
beads. The beads contain iron, and are collected by placing the microfuge tubes on a magnetic 
stand. After GLOBINclear the RNA is analyzed by Nanodrop spectroscopy, then its quality was 
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examined using an Agilent BioAnalyzer to ensure pure, intact RNA for microarray hybridization. 
Next, the BioAnalyzer requires exactly one micro liter of sample in a Nano chip with various 
dyes to determine the RNA integrity number (RIN), which quantifies any degradation the RNA 
may have experienced. An electropherogram conveys visual information about the RNA quality. 
 
 




 The RNA is reverse transcribed to complementary DNA, and hybridized to an 
oligonucleotide microarray which detects approximately 47,000 genes of known sequence. The 
controls include non-addicted individuals’ RNA, as well as the Universal Human Reference 
RNA. After scanning the array, each spot is red or green due to fluorescent dye, and the 
Page 17 
brightness is quantified.  
 A DNA microarray is an ordered array of nucleic acids that enables parallel analysis of 
complex biochemical samples (Schena et al, 1995). This tool for understanding genes and 
mutations involves a collection of microscopic spots of DNA attached to a glass, plastic, or 
silicon forming an array for the purpose of monitoring expression levels for thousands of genes 
simultaneously (called expression profiling). In a spotted microarray, the probes are oligo DNA 
or 70 base sequences. The array is hybridized with DNA from two samples to be compared, such 
as the experimental sample and a Universal Human Reference RNA, labeled with two different 
colors of fluorescent dye. The samples are mixed and hybridized to the microarray, which is then 
scanned, allowing visualization of up-regulated and down-regulated genes at the same time.  
 
Figure 9. Theory of Microarray technology. Image from “Chemistry Online:  An Approach 




Figure 10. DNA hybridization to a microarray.  
On the molecular level, DNA binds to the oligo DNA on the microarray plate at complementary 









One hundred and sixteen blood samples had RNA extracted and purified for downstream 
microarray hybridization, which is currently taking place. Blood samples were collected in 
duplicate to ensure a sufficient quantity of RNA. The samples varied in quality and quality, and 
identical samples were often pooled for microarray hybridization. The hemoglobin transcripts 
were removed, and the purity of RNA was tested on the Bioanalyzer from Agilent. It has yet to 
be determined what the cutoff should be for an acceptable RIN, but higher is better. As shown in 
the post-GLOBINclear data in Figure 11, multi-drug use is common among cocaine dependent 
individuals. Clinical diagnosis was based on a battery of psychological tests. These patients were 
included in a list of de-classified diagnoses sent by UTHSC-Houston, and are representative of 
the hundreds of extracted and purified samples of RNA in this experiment.  
Sample ID RNA (ng/ul) Total RNA (ug) RIN Diagnosis 
10461 #1 81.9 3.24 8.00 Cocaine Dependence 
10461 #2 58.32 3.49 7.90 Cocaine Dependence 
10479 #1  51.17 2.13 7.70 Cocaine/Alcohol Dependence 
10479 #2 90.87 4.54 8.10 Cocaine/Alcohol Dependence 
10481 #1 19.8 2.18592 n/a Cocaine Dependence 
10481 #2 8.1 1.0854 1.1 Cocaine Dependence 
10484 #1 28.15 3.25414 8.3 Cocaine Dependence 
10484 #2 29.39 3.503288 8.4 Cocaine Dependence 
10485 #1 22.95 3.1212 8.1 Cocaine Dependence/Antisocial Person 
10485 #2 7.92 0.899712 8.4 Cocaine Dependence/Antisocial Person 
10486 #1 8.45 1.1154 7.9 Cocaine Dependence, moderate; Alcohol 
10486 #2 21.44 2.718592 7.8 Cocaine Dependence, moderate; Alcohol 
10488 #1 73.94 4.81 7.2 Cocaine/Alcohol Dependence 
10488 #2 54.64 3.38 5.9 Cocaine/Alcohol Dependence 
10489 #1 63.21 4.02 7 Cocaine Dependence, severe; Cannabis 
10489 #2 22.52 1.37 7.3 Cocaine Dependence, severe; Cannabis 
10497 #1 70.5 8.3754 5.7 Cocaine Dependence, severe; Cannabis 
10497 #2 32.1 4.09596 n/a Cocaine Dependence, severe; Cannabis 
 




 Upon initial extraction from whole blood, the quantity of RNA was typically several 
micrograms (Figure 12 shows two representative samples which are followed throughout the 
entire methodology). RNA was concentrated by ethanol precipitation, then the RNA pellet was 
resuspended in a smaller volume of nuclease-free water for stable storage. A dilution of this 
volume was measured with Nanodrop spectroscopy, as shown in Figure 13. After GLOBINclear, 
whether due to degradation over time, microscopic impurities, or due to removal of globin 
transcripts directly, RNA quantity may decrease below the 1 µg limit required for microarray 
hybridization (Figure 14).  
 For each sample the 260:280 and 260:230 absorbance ratios were recorded. If the 
260:280 ratio is below 1.8, the sample is likely contaminated with protein, phenol, or other 
organic reagents used in isolation of the nucleic acid (Thermo Scientific, 2008). The 260:230 
ratio is a secondary measure of purity of nucleic acids, and a ratio lower than 2.0 may indicate 
the presence of EDTA or carbohydrates in the sample. The peak concentration on each 
absorbance diagram, occurs at 260 nm, indicating that nucleic acid is indeed the predominant 
component of the samples.  
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Figure 12. (a) Sample 266 after extraction (b) Sample 224 after extraction. The initial 260/280 
and 260/230 ratios are comparable and of good quality. The 260/280 and 260/230 ratios are 
indicated in the red boxes, and the peak concentration, indicated by a vertical red arrow, is 
always at 260 nm. Thus nucleic acid is the major component of the samples.  
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Figure 13. (a) Sample 266 before GLOBINclear (b) Sample 224 before GLOBINclear. Some 
RNA is lost when prepared for ethanol precipitation, but the vast majority is still available. 
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Figure 14. (a) Sample 266 after GLOBINclear (b) Sample 224 after GLOBINclear, now 











Figure 15. (a) Sample 229 electropherogram (b) Sample 266 electropherogram  
(c) Ideal sample electropherogram (Agilent, USA) 
 
Each peak in the electropherogram represents a subunit. In the ideal sample, the marker peak 
is of significant height, but small compared to the 18S and 28S subunits (Figure 15 c). This is 
true of sample #266 as well, Figure 15 b, which is of good quality. However, for sample 229, the 
18S and 28S subunits form small peaks relative to the marker, indicating degradation of RNA 
(Figure 15 a). The yield of pure RNA after purification by GLOBINclear ranged from 3.553 to 
7.946 micrograms per blood sample (where duplicate samples were taken from each patient), and 
the RNA integrity number, on a scale from 1 to 10, with 10 being the highest quality, ranged 
from 1.10 to 8.80, or from degraded to high quality RNA.  
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IV. Discussion and Applications 
The need for diagnostic biomarkers of addiction is evident. Early diagnosis can permit 
initiation of treatment before the disease progression becomes severe. A quantitative test for 
cocaine dependence can help those who might otherwise slip through the cracks of our 
healthcare system. This project will ultimately produce useful data on such biomarkers of 
cocaine addiction. It can help clinicians to diagnose addicts and to determine what drugs a 
patient has been using long term.  
The project is a collaboration that will discover correlations between gene expression 
patterns and subject behavior as reported by UTMB Galveston and UTHSC-Houston, thus 
enabling unambiguous diagnosis of addiction. As part of the Mayfield lab, my work in RNA 
extraction and purification has provided hundreds of samples of transcripts from cocaine 
dependent individuals, including multi-drug users. These samples are used for ongoing 
microarray hybridization and will eventually contribute to publication. Preliminary findings of 
differentially expressed genes in cocaine-dependent versus cocaine and alcohol dependent 
individuals (thus alcohol-related gene expression) included immune response signals, cell 
adhesion molecules, and the GABA alpha 6 receptor. GABA is the major inhibitory 
neurotransmitter in the brain (Mitchell et al, 2008). At this point, more research is necessary to 
perform additional microarray hybridization and to statistically analyze existing information. 
However, it is hypothesized that significant changes in biomarkers in blood will be found. 
Although brain tissue studies reveal relatively small, 20-50% changes in gene expression due to 
disease states (such as alcoholism, Liu et al, 2004), blood sample studies often indicate larger, 
150% changes in gene expression levels (Sekiguchi et al, 2008).  
The impact of this research includes accurate biochemical diagnosis of addiction or 
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susceptibility.  Early diagnosis is critical to initiating treatment of at-risk individuals. Armed 
with a set of specific biomarkers of cocaine dependence, clinicians could predict disease and 
treatment results based on previous patients’ successes.  
Identification of previously unsuspected biomarkers could reveal novel targets for 
pharmacotherapy development. In this manner normal levels of transcripts could be maintained 
in spite of the tolerance and craving experienced by addicted individuals struggling to quit using 
cocaine. Such drug therapy can make addiction a treatable, manageable disease, and control 
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